Who is actually suitable for GLP-1 treatment in India?
Updated: Oct 1
Eligibility is a medical decision
A social-media trend or a desire to lose a few kilograms is not the same as a clinical indication. Obesity pharmacotherapy is intended for patients whose health profile meets recognised criteria and for whom the expected benefit justifies treatment.
The Endocrine Society of India 2025 guidance recommends considering pharmacotherapy at BMI above 27 kg/m², or above 25 kg/m² with at least one obesity-associated comorbidity such as hypertension, dyslipidaemia, type 2 diabetes or obstructive sleep apnoea.
Indian risk cannot be understood from BMI alone
Asian Indian populations can develop cardiometabolic risk at lower BMI levels than some other populations. Central adiposity and waist circumference therefore add useful information.
A patient with a modest BMI but significant abdominal adiposity, diabetes risk, hypertension or dyslipidaemia may have a very different clinical picture from someone with the same BMI and no metabolic abnormalities.
Medical history matters
Pregnancy, relevant gastrointestinal conditions, previous adverse reactions, diabetes medicines and other health issues can change the benefit-risk calculation. Product-specific contraindications must also be considered.
This is why a prescriber should know more than your height and weight before recommending treatment.
Treatment goals should be clinically meaningful
The goal might include reducing obesity-related risk, improving glycaemic control, reducing waist circumference, improving mobility or supporting longer-term weight management. It should not simply be 'as much weight as possible'.
A good plan defines what success means and how it will be measured.
Sometimes the right answer is no
A safe service should be comfortable deciding that a patient is not suitable, that more information is needed, or that another approach is more appropriate. That independence is an important part of clinical trust.
References
Endocrine Society of India. Clinical Practice Guidelines for the Evaluation and Management of Obesity in India: 2025 Update. PubMed Central (PMC)
American Diabetes Association. Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity. 2026. DOI
CDSCO. SEC Recommendations relating to Wegovy/semaglutide in India.
Written and clinically reviewed by: Dr Saran Seker, MBBS (Aus), Chief Medical Officer
Last reviewed: September 2026
Comments